Skip to main
DWTX

DWTX Stock Forecast & Price Target

DWTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Dogwood Therapeutics Inc is positioned positively due to its innovative product candidates aimed at addressing significant medical needs, particularly for diseases linked to viral immune responses, which broadens its potential market. The recent licensing agreement with Serpin Pharma for the global rights to SP16 empowers Dogwood to explore new opportunities in treating cancer-related pain, which could enhance future revenue streams. Furthermore, the anticipation of initiating the SP16 clinical program and potential partnerships for development and licensing indicates a proactive strategy that may attract investor interest and drive stock performance.

Bears say

Dogwood Therapeutics Inc, a development-stage biotechnology company, faces a negative outlook primarily due to its limited commercialization prospects and reliance on unproven product candidates, IMC-1 and IMC-2. Despite a low dropout rate of 4.4%, which suggests potential patient satisfaction, the company’s focus on developing therapies for niche conditions like fibromyalgia and long COVID poses significant market risk. Financial uncertainties are compounded by the inherent challenges in advancing novel antiviral treatments and the competitive landscape of the biotechnology sector, raising concerns over the company's long-term viability and growth potential.

DWTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dogwood Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dogwood Therapeutics, Inc. (DWTX) Forecast

Analysts have given DWTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, DWTX has a Strong Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dogwood Therapeutics, Inc. (DWTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.